Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern

Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted bivalent COVID-19 vaccine or recovered from BA.4/BA.5 infection, we an...

Descripción completa

Detalles Bibliográficos
Autores principales: Diem, Gabriel, Dichtl, Stefanie, Zaderer, Viktoria, Lass-Flörl, Cornelia, Reindl, Markus, Lupoli, Gaia, Dächert, Christopher, Muenchhoff, Maximilian, Graf, Alexander, Blum, Helmut, Keppler, Oliver T., Wilflingseder, Doris, Posch, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581068/
https://www.ncbi.nlm.nih.gov/pubmed/37551989
http://dx.doi.org/10.1128/spectrum.01793-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581068/
https://www.ncbi.nlm.nih.gov/pubmed/37551989
http://dx.doi.org/10.1128/spectrum.01793-23

Ejemplares similares